A DNA vaccine against extracellular domains 1-3 of flk-1 and its immune preventive and therapeutic effects against H22 tumor cell in vivo

World Journal of Gastroenterology : WJG
Fan LuYi-Min Li

Abstract

To construct a DNA vaccine against extracellular domains 1-3 of fetal liver kinase-1 (flk-1), and to investigate its preventive and therapeutic effect against H22 cell in vivo. Flk-1 DNA vaccine was produced by cloning extracellular domains 1-3 of flk-1 and by inserting the cloned gene into pcDNA3.1 (+). Fifteen mice were divided into 3 groups and inoculated by vaccine, plasmid and saline respectively to detect specific T lymphocyte response. Thirty Mice were equally divided into preventive group and therapeutic group. Preventive group was further divided into V, P, and S subgroups, namely immunized by vaccine, pcDNA3.1 (+) and saline, respectively, and attacked by H22 cell. Therapeutical group was divided into 3 subgroups of V, P and S, and attacked by H22, then treated with vaccine, pcDNA3.1 (+) and saline, respectively. The tumor size, tumor weight, mice survival time and tumor latency period were compared within these groups. Furthermore, intratumoral microvessel density (MVD) was assessed by immunohistochemistry. DNA vaccine pcDNA3.1 (+) flk-1-domains 1-3 was successfully constructed and could raise specific CTL activity. In the preventive group and therapeutic group, tumor latency period and survival time were significant...Continue Reading

References

Dec 16, 1992·Journal of the National Cancer Institute·N WeidnerG Gasparini
Oct 26, 1999·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·H YoshijiH Fukui
May 10, 2000·The Oncologist·G McMahon
Feb 17, 2001·Journal of Hepato-biliary-pancreatic Surgery·S KarademirI Astarcioğlu
May 10, 2001·Cell Structure and Function·M Shibuya
Jul 11, 2001·Immunologic Research·J E Ohm, D P Carbone
Sep 29, 2001·Drug Discovery Today·A Matter
Dec 1, 2001·Expert Opinion on Biological Therapy·T G Zogakis, S K Libutti
Mar 23, 2002·Experimental Biology and Medicine·Katharina HauptKlauss Mann
Nov 30, 2002·Trends in Pharmacological Sciences·Andreas Bikfalvi, Roy Bicknell
Nov 30, 2002·Medical Microbiology and Immunology·A Henke
Dec 21, 2002·Nihon yakurigaku zasshi. Folia pharmacologica Japonica·Masabumi Shibuya
Dec 24, 2002·Cancer Biology & Therapy·Christian M BeckerBruce R Zetter
Jun 6, 2003·Cancer Detection and Prevention·D BisacchiA Albini
Sep 10, 2003·Seminars in Oncology Nursing·Paula M Muehlbauer
Oct 18, 2003·Laboratory Investigation; a Journal of Technical Methods and Pathology·Satoko YoshidaMasataka Majima
Nov 26, 2003·Nihon yakurigaku zasshi. Folia pharmacologica Japonica·Masabumi Shibuya
Jan 2, 2004·Breast Cancer Research and Treatment·Lisa RydénGöran Landberg

❮ Previous
Next ❯

Citations

Mar 8, 2006·European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology·Y OkajiK Takahashi
May 16, 2007·Cancer Immunology, Immunotherapy : CII·Debra KamstockSteven Dow

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Vaccines

Cancer vaccines are vaccines that either treat existing cancer or prevent development of a cancer.

Avian Influenza: Innate Immune Adjuvant

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.

Avian Influenza: Innate Immune Adjuvant (ASM)

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.